ArticleOncotarget2017
Verteporfin inhibits gastric cancer cell growth by suppressing adhesion molecule FAT1.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 34 citations in OpenAlex.
- Molecular Mechanisms of FAT Atypical Cadherin 1 (FAT1), the Hippo Pathway, and the Yes-Associated Protein (YAP) Signaling Pathways in Some Cancers.Asian Pacific journal of cancer prevention : APJCP · 2026Review
- Hippo-YAP/TAZ signaling in gastric cancer: molecular pathogenesis and emerging therapeutic horizons.Medical oncology (Northwood, London, England) · 2026Review
- Synergizing photodynamic therapy and ethanol ablation: Light-activatable sustained-exposure ethanol injection technology for enhanced tumor ablation.Bioengineering & translational medicine · 2025Article
- Immune factors and their role in tumor aggressiveness in glioblastoma: Atypical cadherin FAT1 as a promising target for combating immune evasion.Cellular & molecular biology letters · 2025Review
- Label-free quantitative proteomics of gastric high-grade intraepithelial neoplasia.Experimental and therapeutic medicine · 2025Article
- Recent advances in the role of atypical cadherin FAT1 in tumorigenesis (Review).Oncology letters · 2025Review
- Evaluation of Verteporfin as a Photosensitizer With Anticancer Activity Via System Biology Tools.Journal of lasers in medical sciences · 2025Article
- Novel artificial intelligence-based identification of drug-gene-disease interaction using protein-protein interaction.BMC bioinformatics · 2024Article
- Diffuse Gastric Cancer: A Comprehensive Review of Molecular Features and Emerging Therapeutics.Targeted oncology · 2024Review
- Review
- Hippo pathway dysregulation in gastric cancer: from Helicobacter pylori infection to tumor promotion and progression.Cell death & disease · 2023Review
- Oncogenic LINC00857 recruits TFAP2C to elevate FAT1 expression in gastric cancer.Cancer science · 2023Article
- Repurposed Drugs in Gastric Cancer.Molecules (Basel, Switzerland) · 2022Review
- The diverse functions of FAT1 in cancer progression: good, bad, or ugly?Journal of experimental & clinical cancer research : CR · 2022Review
- Hippo in Gastric Cancer: From Signalling to Therapy.Cancers · 2022Review
- Molecular profile of pure squamous cell carcinoma of the bladder identifies major roles for OSMR and YAP signalling.The journal of pathology. Clinical research · 2022Article
- Photosensitizer verteporfin inhibits the growth of YAP- and TAZ-dominant gastric cancer cells by suppressing the anti-apoptotic protein Survivin in a light-independent manner.Oncology letters · 2021Article
- Role of FAT1 in health and disease.Oncology letters · 2021Review
- Identification of the atypical cadherin FAT1 as a novel glypican-3 interacting protein in liver cancer cells.Scientific reports · 2021Article
- Matrix stiffness epigenetically regulates the oncogenic activation of the Yes-associated protein in gastric cancer.Nature biomedical engineering · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
Gastric cancer (GC) is a leading cause of death worldwide and in urgent need of targeted drug development. In the current, we investigated the ability of a repositioned drug verteporfin (VP), originally a treatment for macular degeneration, to inhibit GC cell growth. VP inhibited growth of various GC cell lines. Gene expression profiling of GC cell lines treated with VP revealed that migration-related genes and those with oncogenic potential were down-regulated. Of these genes, we found that FAT1, an adhesion molecule promoting cell invasion, was highly suppressed by VP. Silencing of FAT1 suppressed cell migration and invasion as VP did. FAT1 expression was up-regulated in tumors, and patients with high FAT1-expressing tumors had a worse prognosis. We propose that VP- targeting FAT1 to suppress metastatic potential is a promising therapeutic strategy against GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.